Cognetivity Neurosciences Ltd.
CGN
CNSX
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -35.49% | -55.79% | -22.21% | -106.87% | -72.93% |
| Gross Profit | 39.41% | 58.15% | 22.79% | 112.57% | 72.93% |
| SG&A Expenses | -4.82% | -43.74% | -45.31% | -62.08% | -87.91% |
| Depreciation & Amortization | 4.08% | 7.55% | 0.00% | -40.98% | -7.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.29% | -49.29% | -28.38% | -73.92% | -71.31% |
| Operating Income | 50.90% | 50.44% | 28.64% | 74.76% | 71.31% |
| Income Before Tax | -11.15% | -17.40% | -32.75% | 53.66% | 71.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.15% | -17.40% | -32.75% | 53.56% | 71.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.15% | -17.40% | -32.75% | 53.56% | 71.91% |
| EBIT | 50.90% | 50.44% | 28.64% | 74.76% | 71.31% |
| EBITDA | 51.11% | 50.68% | 28.76% | 74.81% | 71.38% |
| EPS Basic | 0.00% | -7.05% | -13.75% | 56.25% | 74.78% |
| Normalized Basic EPS | -4.72% | -16.49% | -11.00% | 56.56% | 74.76% |
| EPS Diluted | 0.00% | -7.05% | -13.75% | 56.25% | 74.78% |
| Normalized Diluted EPS | -4.72% | -16.49% | -11.00% | 56.56% | 74.76% |
| Average Basic Shares Outstanding | 11.29% | 9.67% | 17.25% | 6.22% | 11.43% |
| Average Diluted Shares Outstanding | 11.29% | 9.67% | 17.25% | 6.22% | 11.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
